Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07491458 · ClinicalTrials.gov registry record · Phase 2
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
A Phase 2 study, sponsored by Rivus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT07491458 is a Phase 2 study that is actively recruiting participants, run by Rivus Pharmaceuticals. The registered enrollment target is 180 participants.
The verdict
NCT07491458, a Phase 2 study, is actively recruiting participants, sponsored by Rivus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also assess safety, pharmacokinetics (PK) and changes in liver fat content related to patients diagnosed with MASH.
Interventions
- OTHER Placebo
- DRUG HU6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07491458
The ClinicalTrials.gov registry entry for NCT07491458 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rivus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07491458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07491458 about?
NCT07491458 is a clinical study titled "A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)". Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also assess safety, pharmacokinetics (PK) and changes in liver fat co...
What is the current status of trial NCT07491458?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2026-02-13. Estimated completion is 2028-02.
What interventions are being tested in trial NCT07491458?
The interventions under investigation include: Placebo (OTHER), HU6 (DRUG).
Who is sponsoring clinical trial NCT07491458?
This trial is sponsored by Rivus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.